Progress in the Application of Novel Nanomaterials in Targeted Therapy for Liver Cancer

被引：0

作者：

Wei, Xin ^{[1
]}

Cao, Weihua ^{[1
]}

Wang, Shiyu ^{[1
]}

Zhang, Yaqin ^{[1
]}

Gao, Zixuan ^{[1
]}

Wang, Shuojie ^{[1
]}

Yao, Linmei ^{[1
]}

Zhang, Ziyu ^{[1
]}

Li, Xinxin ^{[1
]}

Deng, Wen ^{[1
]}

Xie, Yao ^{[1
,2
]}

Li, Minghui ^{[1
,2
]}

机构：

[1] Capital Med Univ, Beijing Ditan Hosp, Dept Hepatol Div 2, Beijing 100015, Peoples R China

[2] Peking Univ Ditan Teaching Hosp, Dept Hepatol Div 2, Beijing, Peoples R China

来源：

INTERNATIONAL JOURNAL OF NANOMEDICINE | 2025年 / 20卷

关键词：

liver cancer; targeted therapy; nanotechnology; drug delivery; nanoparticles; MESOPOROUS SILICA NANOPARTICLES; HEPATOCELLULAR-CARCINOMA; SILVER NANOPARTICLES; GOLD NANOPARTICLES; DRUG-DELIVERY; BIOMEDICAL APPLICATIONS; CHITOSAN NANOPARTICLES; OPEN-LABEL; IN-VITRO; SORAFENIB;

D O I：

10.2147/IJN.S509409

中图分类号：

TB3 [工程材料学];

学科分类号：

0805 ; 080502 ;

摘要：

In recent years, nanobiotechnology, widely used in hepatoma, holds great promise for improving targeted hepatocarcinoma therapy. On account of the unique properties of low toxicity, good tolerance, biocompatibility, and biodegradability of new nanomaterials, a targeted drug delivery system (TDDS) has been constructed, which can boost the therapeutic effect of hepatomatargeted drugs, reduce drug toxicity, and minimize off target reactions by enhancing permeability retention effect (EPR) and active targeting, thus improving existing liver cancer targeted therapy strategies. Different nanoparticles have their own advantages and disadvantages. They can be loaded with multiple drugs on the same nanoparticle and can also be surface modified with each other to achieve synergistic anti-tumor effects. This essay provides a comprehensive overview of the current status of targeted therapy for hepatocarcinoma, nanoparticles' structure, advantages and disadvantages of each nanoparticle, and the application progress of nanoparticles in targeted therapy for liver cancer. We hope to provide a basis for the future clinical targeted therapy of hepatoma using nanotechnology.

引用

页码：2623 / 2643

页数：21

共 168 条

[1] Hwang SY, Danpanichkul P, Agopian V., Et al., Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment, Clin Mol Hepatol, 2024, (2024)
[2] Lazzaro A, Hartshorn KL., A Comprehensive Narrative Review on the History, Current Landscape, and Future Directions of Hepatocellular Carcinoma (HCC) Systemic Therapy, Cancers, 15, 9, (2023)
[3] Gujarathi R, Klein JA, Liao C-Y, Pillai A., The Changing Demographics and Epidemiology of Hepatocellular Carcinoma, Clin Liver Dis, 29, 1, pp. 1-15, (2025)
[4] Koshy A., Evolving Global Etiology of Hepatocellular Carcinoma (HCC): insights and Trends for 2024, J Clin Exp Hepatol, 15, 1, (2025)
[5] Electronic address: easloffice@easloffice.eu & European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma, J Hepatol, 69, 1, pp. 182-236, (2018)
[6] Zhou J, Sun H, Wang Z., Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition), Liver Cancer, 12, 5, pp. 405-444, (2023)
[7] Yang X, Yang C, Zhang S., Precision treatment in advanced hepatocellular carcinoma, Cancer Cell, 42, 2, pp. 180-197, (2024)
[8] Liu X, Bai Y, Zhou B., Recent advances in hepatocellular carcinoma-targeted nanoparticles, Biomed Mater, 19, 4, (2024)
[9] Escutia-Gutierrez R, Sandoval-Rodriguez A, Zamudio-Ojeda A, Guevara-Martinez SJ, Armendariz-Borunda J., Advances of Nanotechnology in the Diagnosis and Treatment of Hepatocellular Carcinoma, J Clin Med, 12, 21, (2023)
[10] Yang S-L, Xiang Y, Yang Y-J., Advances in Nanotechnology-Based Drug Delivery Systems in the Treatment of Hepatocellular Carcinoma, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 46, pp. 384-392, (2024)

← 1 2 3 4 5 6 7 8 9 10 →